Emmaus Life Sciences, Inc.

EMMA

US29137T1016

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 16:35:45 14/05/2024 BST			5-day change	1st Jan Change
0.103 ^USD	-1.90%		-6.36%	+2.90%

02-02	Emmaus Life Sciences, Inc. Receives Marketing Authorization from the Puerto Rico Department of Health for Endari® (L-Glutamine Oral Powder)	CI
2023	Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q3 Revenue $5M	MT

Emmaus Life Sciences, Inc. Announces Resignation of Robert Dickey IV as Director

August 10, 2022 at 09:03 pm

Emmaus Life Sciences, Inc. announced that Robert Dickey IV resigned as a director of the company over a disagreement with management of the company.

Latest news about Emmaus Life Sciences, Inc.

Emmaus Life Sciences, Inc. Receives Marketing Authorization from the Puerto Rico Department of Health for Endari® (L-Glutamine Oral Powder)	02-02	CI
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q3 Revenue $5M	11-14	MT
Emmaus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Emmaus Life Sciences, Inc. Announces Board Changes	04/10/23	CI
Emmaus Life Sciences, Inc. Announces Yutaka Niihara No Longer Serve as Chief Executive Officer	23/08/23	CI
Emmaus Life Sciences, Inc. Announces Management Changes	23/08/23	CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Emmaus Life Sciences, Inc Receives Marketing Authorization for EndariÂ® in Oman	13/07/23	CI
Emmaus Life Sciences, Inc. Receives Medicine Registration Certificate from the Bahrain National Health Regulatory Authority	31/05/23	CI
Emmaus Life Sciences, Inc. Receives Medicine Registration Certificate from the Bahrain National Health Regulatory Authority	31/05/23	CI
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q1 Revenue $6.8M	15/05/23	MT
Emmaus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Emmaus Life Sciences, Inc. Auditor Raises 'Going Concern' Doubt	30/03/23	CI
Emmaus Life Sciences, Inc. Receives Kuwaiti Marketing Authorization	07/12/22	CI
Emmaus Life Sciences, Inc. Receives Endari Marketing Authorization from the Qatar Ministry of Public Health	17/11/22	CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Emmaus Life Sciences, Inc. Announces Board Changes	06/10/22	CI
Emmaus Life Sciences, Inc. Announces Resignation of Masaharu Osato as Member of the Board of Director	30/09/22	CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
Emmaus Life Sciences, Inc. Announces Resignation of Robert Dickey IV as Director	10/08/22	CI
Emmaus Life Sciences, Inc. Announces Resignation of Executives	10/06/22	CI
Earnings Flash (EMMA) EMMAUS LIFE SCIENCES Posts Q1 Revenue $3.2M	13/05/22	MT
Emmaus Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
Emmaus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	31/03/22	CI

Chart Emmaus Life Sciences, Inc.

Duration

Period

More charts

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing, and sale of treatments and therapies, primarily for rare and orphan diseases. The Companyâs lead product, Endari (prescription-grade L-glutamine oral powder), helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients aged five years and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainosâs IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. It has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells.

Sector

Biotechnology & Medical Research

Calendar

11/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EMMAUS LIFE SCIENCES, INC.	+2.90%	6.71M
MODERNA, INC.	+29.03%	48.16B
IQVIA HOLDINGS INC.	-0.10%	41.73B
LONZA GROUP AG	+43.45%	41.03B
CELLTRION, INC.	-5.26%	28.77B
ICON PUBLIC LIMITED COMPANY	+11.48%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.96B
BIO-TECHNE CORPORATION	+9.06%	12.92B
MEDPACE HOLDINGS, INC.	+30.01%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.77B

Other Biotechnology & Medical Research